Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPOSE: 177Lu-Edotreotide vs Standard of Care in Aggressive GEP-NETs
NCT04919226Phase 3Active, not recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Dec 2021
- Primary completion
- Jun 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by ITM Isotope Technologies Munich. Primary endpoint: Progression-Free Survival. Started Dec 2021; status: active, not recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04919226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919226.